Key result
Landiolol safely controlled rapid atrial fibrillation in patients with acute decompensated HFrEF, leading to hemodynamic improvement and avoidance of short-term major adverse events.
Why the study?
Does landiolol safely reduce heart rate and improve hemodynamics without increasing major adverse events in patients with ADHF, HFrEF, and rapid AF?
Does landiolol safely reduce heart rate and improve hemodynamics without increasing major adverse events in patients with ADHF, HFrEF, and rapid AF?
Answers are grounded in this paper and cite their sources.
Supports landiolol exploration for rapid AF in acute decompensated HFrEF; hypothesis-generating, should not yet change practice.
Landiolol was effective for safely controlling rapid AF in patients with HFrEF with ADHF, leading to hemodynamic improvement and avoidance of short-term MAE, especially in patients with relatively smaller LV and higher BP.
No takes yet. Share an insight, caveat, or question.
Iwahashi et al. (2019) studied this question. Landiolol safely controlled rapid atrial fibrillation in patients with acute decompensated HFrEF, leading to hemodynamic improvement and avoidance of short-term major adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: